title: Chronic pouchitis after ileal pouch-anal anastomosis: responses to butyrate and glutamine suppositories in a pilot study.
abstract: Nonspecific, idiopathic inflammation of ileal pouch mucosa ("pouchitis") after ileal pouch-anal anastomosis is a common complication of this surgical approach. The epithelium of the pouch is ileal, but variable degrees of colonic metaplasia are natural sequelae of construction of such a pouch. One hypothesis is that pouchitis is caused by a deficiency of epithelial nutrition. Thus, a lack of butyric acid (the principal metabolic fuel of colonocytes) or of glutamine (the main fuel of enterocytes) may develop. In this study, our aims were to determine the concentration of total short-chain fatty acids in random stool samples obtained from patients with an ileal pouch-anal anastomosis with and without pouchitis and to test the therapeutic effects of butyrate and glutamine suppositories on pouchitis. During the study, all conventional therapy for pouchitis was discontinued. For 21 days, 9 patients participated in a butyrate trial, and 10 patients were treated with glutamine. Total concentrations of fecal short-chain fatty acids were significantly less in patients with pouchitis than in those without pouchitis. During treatment, 6 of the 10 patients who received glutamine had no recurrence of symptoms, but only 3 of the 9 patients who received butyrate responded similarly. Hence, further studies of glutamine in the treatment of pouchitis seem warranted.
authors.affiliation: Gastroenterology Research Unit, Mayo Clinic Rochester, MN 55905.
authors.forename: P
authors.initials: P
authors.lastname: Wischmeyer
authors.forename: J H
authors.initials: JH
authors.lastname: Pemberton
authors.forename: S F
authors.initials: SF
authors.lastname: Phillips
mesh_terms: D000293:Adolescent; D000328:Adult; D002087:Butyrates / Q000627:therapeutic use*; D020148:Butyric Acid; D002908:Chronic Disease; D005232:Fatty Acids, Volatile / Q000032:analysis; D005243:Feces / Q000737:chemistry; D005260:Female; D005973:Glutamine / Q000627:therapeutic use*; D006801:Humans; D007249:Inflammation; D007410:Intestinal Diseases / Q000188:drug therapy* / Q000209:etiology* / Q000378:metabolism; D007413:Intestinal Mucosa / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D016737:Proctocolectomy, Restorative / Q000009:adverse effects*; D013488:Suppositories; D016896:Treatment Outcome
chemical_list: D002087:Butyrates; D005232:Fatty Acids, Volatile; D013488:Suppositories; D005973:Glutamine; D020148:Butyric Acid